NCI-H82 In Vivo Metastasis Assay

This assay is to provide NCI-H82-based In Vivo Metastasis Assay to accelerate our client's oncology projects. The assay will be customized according to the specific requirements. Please contact our scientists to discuss more details.

NCI-H82

Human

The NCI-H82 cell line was derived by A.F. Gazdar and associates in 1978 from the pleural fluid of a patient with small cell cancer of the lung. The NCI-H82 cell line was derived by A.F. Gazdar and associates in 1978.

H82

Lung Cancer

Oncology

In Vivo Metastasis Assay

Metastasis is defined as the formation of tumors that are discontinuous from the primary tumor. These secondary tumors can be at nearby or distant sites and can form, following the dissemination of cells via lymphatic, hematogenous, coelomic cavities, or epithelial cavities. Metastasis is not equivalent to invasion, adhesion, growth rate, susceptibility to immune cell killing, or any of the many steps in the metastatic cascade. These processes are necessary for successful colonization of the secondary sites, but they are not sufficient for a cell to be metastatic. Analysis of tumor growth and metastasis of human cancers requires the use of immunodeficient animals. Please contact us to learn more and offer the best-fit proposals for your program.

Oncology In Vivo Assays